PRESS RELEASE No. 057/KFCP-DIR/PR/VIII/22
Jakarta, August 22nd, 2022 – PT Kalbe Farma Tbk (Kalbe) is accelerating the effort to decrease the rate of stunting. The 2019 survey data of nutrition status of toddlers in Indonesia, or SSGBI, revealed that the stunting rate in Indonesia had reached 27,67 percent. Therefore, President Joko Widodo or Jokowi has targeted that the prevalence of stunting in Indonesia must be below 14 percent by 2024.
“Stunting is a growth disorder on children marked by a non-ideal body height for children above two years old, or below the green mark of comparison curve on height and age,” as stated by the Head of Kalbe Nutritionals Research Center of PT Kalbe Farma Tbk, dr. Iwan Surjadi Handoko, in an Instagram Live of @ptkalbefarmatbk.
He then added, “Stunting is caused by repetitive or prolonged malnutritions, therefore it was more considered as a syndrome or a symptom set rather than a disease.”
According to dr. Iwan, the main cause, which was the malnutrition on babies, could happen when they were in their mothers’ wombs, in which their mothers experienced a lack of nutritions or nutrient absorptions. Unhealthy food habits, which caused them to contract flu, coughing, to diarrhea, prevented the mothers to fully absorb the nutrients for their babies.
The stunting issue has become a focus for Kalbe Farma through a sustainable initiative, which is in accordance with its tagline, “Together We Heal the Nation”. The sustainability report on stunting was already conducted in 2019 in East Nusa Tenggara, followed by Sleman and Madiun in 2021, through collaborations with BKKBN and KlikDokter in a digital education.
“In 2022, Kalbe collaborated with the Yarsi University once again to battle stunting in a form of a health education, support on nutrient products, the decrease of prevalance on stunting, and researches on measuring the improvement of nutrition as the intended target,” as stated by the Sustainability Manager of PT Kalbe Farma Tbk, Abi Nisaka.
The program is in the form of CSR (Corporate Social Responsibility) through the pillar of Access to Healthcare by PT Kalbe Farma. Abi also revealed that the collaboration with the Yarsi University would last for the next two years, which kicked off at July 15th, 2022.
“PT Kalbe Farma sets a target for this comprehensive program to not only provide supports to the product, but also to conduct researches on comparing the current condition and the condition at the end of the program, which discusses about the nutritional improvement benchmark,” as Abi explained
The target of the stunting collaboration with the Yarsi University is a region in Kresek, Tangerang, according to a program supported by the university. Its location which nears Jakarta also makes it easier to be coordinated, in addition to the readiness of its infrastructures, such as a public health center and a counseling front.
As Abi explained, “There are also an education facility, a nutritional parameter measurement, and a distribution of milk products for pregnant women, which includes its distribution routes and storages. Though the program was initially conducted with 60 pregnant women for six months, there will be an evaluation for its development as the time progresses.”
“Along with the Yarsi University, we try to determine its impacts from the beginning until the next six months. If being reviewed and become better, we will implement it other places. Our hope is whether the nutritional status for mothers can become better at the end of the program, and when the children are born, they will be in optimal conditions and ideal body weights,” as dr. Iwan concluded.
Kalbe at a Glance
Founded in 1966, PT Kalbe Farma Tbk (Kalbe) is one of the largest open pharmaceutical companies in Southeast Asia. The company has four main divisions that engage in a portfolio of reliable and diversed brands, such as the prescription medicine division, the health product division which handles free medicines, multivitamins, and ready-to-drink supplement beverages, and the distribution and logistics divisions.
Kalbe has also developed a digital service ecosystem for the society, both in B2B with EMOS and in B2C with KlikDokter. EMOS is an order management application system that facilitates the distribution channels in commencing stock management or supply chain, while KlikDokter is a digital platform for health services, specifically telemedicine, which provides necessary health consultations and products for the society.
Now, Kalbe has more than 40 subsidiaries and 15 production facilities with international standards, employing around 16.000 employees who are being stationed in 76 branches all around Indonesia. Kalbe’s shares has been recorded in the Indonesia Stock Exchange (IDX) since 1991 (IDX:KLBF).